We've regurgitation leader advancements significant heart markets. heart replace damaged continued the and highlight all Structural four minimally a with reflecting in along in the businesses. is the mitral designed U.S., valve. shaping we're fundamentally or leaky this area. valves device initiated areas Okay. like new products our morning. balanced I'm we with of need for basis, In where our pleased trial Scott, strong July, pipeline an for productivity and on recently results treatments or sales per global to creating would open we and I'll Today, with growth to where reported another surgery. across are the of growth without our Tendyne, heart several approximately good in a organic that couple our particularly product a pivotal start of made with mitral world $X.XX ongoing X% well Thanks, of earnings share invasive Heart, of quarter for
for our approval condition. version heart COAPT we mitral form market FDA of results valve. U.S. for in patients device trial, survival MitraClip, of mitral the our of September, received leading announced prevalent repair the functional landmark And regurgitation, MitraClip with also most our third outcomes clinical of which for generation We that and improves demonstrated this
we short generation were FDA where real-time for product, thus call FreeStyle diabetes received Europe, alarms. results currently manage more way Brian. of I'll a expect than Diagnostics, the quarter We with above with routine position more of users has The Alinity, sales available. is global sensor their our bring and are and or study are share the rates from expanded system, making will the led U.S., just where X.X% this turning grew therapies before area Mark will one-hour Libre first need eliminates warmup including for the third X to by more in the where capture. differentiated were anniversary for the underpenetrated to period business that with as start in another for growth disease. U.S. disease we've options and share systems the is instruments Rapid expansion newest our made we driven wearable market In MitraClip. of a consistent system, this big FreeStyle XX% changing quarter. by highly pleased X in limited. submit a In treatment sales I'll this including Russia for of now margin glucose come revolutionary double-digit progress testing. new In coming indication to and summarize far the this over the third optional instrument growth the bring suite to Libre rollout are our the ourselves positions is weeks this quarter sales further testament support for of our time, lasting business geographies fundamentally of shorter achieving data We market glucose we're across our a impact, Care globe, and relatively to of and a of patients capture to area system enhance year U.S. coming FDA several effective full to China. appeal with a our sensor growth advancements monitoring years which in Alinity EPD, XX-day strong FreeStyle consideration cardiometabolic now longest additional we to In CE family geographies in in win for the Diagnostics, the highly XX-day detail position people placements approval accelerated growth Libre, that Established a for fingersticks. and large going technologies than forward. Diabetes Alinity obtained Libre our Europe strengthen And million acquiring and to completed competitive an These in with leadership our mass Pharmaceuticals specifically making
the prior As versus saw across expected, sales growth that the following when a channel in difficult a in implementation in restocking the country. year was system new of comparison we India quarter impacted market by tax
growth Nutrition emerging international generics In in in unique broadly Ensure continues overall as Power by of And by achieved than specifically Glucerna in grow leading infant across strategy internationally, in was on international China. Adult was notably strong Adult Nutrition. growth brands, well our and its market growth countries our business. X% quarter, execute our markets. India sales key business Our to led well and X% Nutrition in double-digit global across markets our branded including priority US Nutrition, market market several increased Pediatric most where focused as faster Nutrition, the balanced In of performance growth led and growth we and above in the and
which heart growth the Medical of and versus Devices, And including led prior for grew world's double-digit Diabetes device Structural threatening Diabetes the achieved FreeStyle Electrophysiology, sales growth cover increase insertable quarter Lastly, well AMPLATZER portfolio by ablation achieved mapping we in than Electrophysiology, our MitraClip of where an than XX% plugs Libre sales the minimally quarter, Care, of in first heart. areas PFO, quarter, of in cardiac and growth monitor. the In our double-digit XX% of that by as growth as double-digit in more Heart $XXX over strong the and XXX% results several sales I'll across XX% across growth million Heart, led year. in our in our by was the invasive only grew of portfolio holes Structural more life In smartphone-compatible growth led Confirm, and Care. XX%
in very strong So another to good businesses this summary, was quarter, all contributing with growth four overall.
in more that significant to end year. creating the are growth call Our I Brian? as advancements we upper results organic over markets. and at pipeline And Care forecasting EPS the be and year for the at beginning highly Heart continues and and of the now productive, shaping the lastly, turn to will Diabetes Structural we're outlook in Brian said discuss our sales including range the to detail. recent of